Authors

Latest:

Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

Joleen Hubbard, MD, Mayo Clinic

Latest:

Dr. Hubbard on the Design of the NRG-GI005 Trial in Colorectal Cancer

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Jon Thorson, PhD

Latest:

Searching Appalachia for Next Great Cancer Drug

The natural products produced by microbes found in the environment have led to major therapeutic breakthroughs for a variety of conditions ranging from infectious disease to cancer.

Jonas de Souza, MD

Latest:

Dr. de Souza on Next Steps for Immunotherapy in Head and Neck Cancer

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Jonathan A. Ledermann, BSc, MD, FRCP

Latest:

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.

Jonathan A. Ledermann, MD

Latest:

Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer

Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.

Jonathan Alicea

Latest:

AKT1 E17K Mutation Targetable in Various Tumors Through AKT Inhibition

A multihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor,

Jonathan Bertman, MD

Latest:

Nothing Is Ever Simple with Windows

In last month's column, I talked about Microsoft's newest desktop operating system, Windows 7, and outlined several reasons why you might want to purchase it when it comes out this year. Windows 7 will include some really cool features-like multi-touch technology and usability improvements-that can benefit medical practitioners and their office staff. Because it is in Microsoft's best interest to make the process of upgrading to Windows 7 simple and straightforward, you would think the software giant would put great effort into streamlining the experience.

Jonathan Bertman, MD, FAAFP

Latest:

Code Overload

The ICD-9 medical coding system we’ve all relied on for decades will soon change.

Jonathan Brammer, MD

Latest:

Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

Jonathan C. Trent, MD

Latest:

Dr. Trent on the Need for Novel Combination Strategies in Metastatic GIST

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

Jonathan C. Trent, MD, PhD

Latest:

Dr Trent on The Current Standard of Care and Existing Unmet Needs for Patients with GIST

Jonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.

Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center

Latest:

TRK Fusion Inhibitors in Clinical Practice

Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

Jonathan D. Schoenfeld, MD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Jonathan D. Schoenfeld, MD, MPH

Latest:

Dr. Schoenfeld on Synergy Between Radiation and Immunotherapy in SCCHN

Jonathan D. Schoenfeld, MD, MPhil, MPH

Latest:

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Jonathan D. Tward, MD, PhD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Jonathan D'Cunha, MD, PhD, FACS

Latest:

Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung Cancer

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Jonathan E. Brammer, MD

Latest:

Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Jonathan E. Rosenberg, MD

Latest:

Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.